Skip to main content
OpenTrials
Completed

NCT Number: NCT01392508

IMproved PREdiction of Severe Sepsis in the Emergency Department

The purposes of this study is to determine whether Heparin Binding Protein (HBP) can be used as a marker of severe sepsis (including septic shock) in patients presenting to the emergency department with suspected infection.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Systemic Inflammatory Response Syndrome (SIRS) Infections Inflammation Pathologic Processes Pathological Conditions, Signs and Symptoms Sepsis Septic Shock Severe Sepsis Shock Shock, Septic Systemic Inflammatory Response Syndrome

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Universitetssjukhuset i Linkoping, Linköping, Sweden

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Greater than or equal to 18 years
  • Suspected Infection
  • one or more SIRS criteria

Sponsors and collaborators

Lead sponsor

Axis Shield Diagnostics Ltd

Industry

Registry information

Official study title

Prospective, Non-interventional, Multi-centre Clinical Study to Assess the Clinical Validity of the Heparin Binding Protein (HBP) Assay for Indicating the Presence, or Outcome, of Severe Sepsis (Including Septic Shock), Over 72 Hours, in Patients With Suspected Infection Following Emergency Department Admission.

Acronym: IMPRESSED

Important dates

Study start
2011
Primary completion
2015
Study completion
2015
First posted
Jul 12, 2011
Registry last updated
Apr 14, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.